Look back at pharma news to Apr 7

tpl-week-in-review-700x466

As we soon head into the first-quarter financial results reporting period, German family-owned pharma major Boehringer Ingelheim came to the fore, reporting its achievements for 2016. Also in the news were positive late-stage clinical results for Paratek Pharmaceuticals’ omadacycline, Astellas Pharma’s buy of Belgian firm Ogeda, lack of investor excitement despite a US approval for Teva Pharmaceutical Industries Huntington’s drug and questions over Tesaro’s PARP inhibitor.

Is this the turnaround Paratek has been looking for?

Shares of Paratek Pharmaceuticals saw a huge gain early on Tuesday after the company provided a critical update on its late-stage pneumonia trial, noted Chris Lang on 24/7WALLSt. Specifically, the firm reported positive top-line results from a global, pivotal Phase III clinical study comparing its once-daily oral and intravenous, broad spectrum investigational antibiotic, omadacycline, to moxifloxacin in the treatment of patients with community-acquired bacterial pneumonia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical